Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Association between amantadine and the onset of dementia in Parkinson's disease

Identifieur interne : 001352 ( Istex/Curation ); précédent : 001351; suivant : 001353

Association between amantadine and the onset of dementia in Parkinson's disease

Auteurs : Rivka Inzelberg [Israël] ; Ubaldo Bonuccelli [Italie] ; Edna Schechtman [Israël] ; Ala Miniowich [Israël] ; Rosa Strugatsky [Israël] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Carlo Rossi [Italie] ; Colin Klein [Israël] ; J. Martin Rabey [Israël]

Source :

RBID : ISTEX:AEBB6144CDA4BCBA8F00BF9EDBF063AD31C40036

English descriptors

Abstract

The objective of this study is to compare the occurrence of dementia among Parkinson's disease (PD) patients treated with amantadine (AM group) with those never exposed to it (NoAM group). PD dementia shares neuroanatomical and biochemical similarities with Alzheimer's disease (AD). Memantine, an N‐methyl‐D‐aspartate (NMDA) receptor antagonist has been shown to be beneficial in AD. Memantine is a dimethyl derivative of amantadine, which also possesses NMDA receptor blocking properties. We hypothesized that amantadine could have a beneficial effect on the occurrence of PD dementia. PD patients attending the Movement Disorders Clinics in Hillel Yaffe, Asaf Harofe Medical Centers (Israel) and Pisa (Italy) were included. Taking the onset of dementia as the endpoint, survival curves for AM and NoAM patients were estimated by the Kaplan–Meier method. The study population consisted of 593 patients (age, 69.5 ± 9.9 years; PD duration, 9.2 ± 6.0 years; 263 patients (44%) amantadine treated). The endpoint of dementia was reached by 116 patients (20%). PD duration until dementia was significantly longer for AM patients (9.1 ± 5.7 years) than for NoAM patients (5.9 ± 4.6 years, P = 0.006). The duration of amantadine exposure positively correlated with PD duration until dementia (P = 0.0001). Survival analysis, taking dementia onset as endpoint, showed slower mental decline in AM patients (Log rank P = 0.0049, Wilcoxon P = 0.0024). Mini‐Mental State Examination scores were significantly higher for AM patients than for the NoAM group (P = 0.01). Age of PD onset also significantly influenced the duration of PD until dementia. Amantadine use may delay the onset of dementia in PD patients and may attenuate its severity. © 2006 Movement Disorder Society

Url:
DOI: 10.1002/mds.20968

Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:AEBB6144CDA4BCBA8F00BF9EDBF063AD31C40036

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Association between amantadine and the onset of dementia in Parkinson's disease</title>
<author>
<name sortKey="Inzelberg, Rivka" sort="Inzelberg, Rivka" uniqKey="Inzelberg R" first="Rivka" last="Inzelberg">Rivka Inzelberg</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurology, Hillel Yaffe Medical Center, Hadera, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Hillel Yaffe Medical Center, Hadera</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurosciences, University of Pisa, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurosciences, University of Pisa</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Schechtman, Edna" sort="Schechtman, Edna" uniqKey="Schechtman E" first="Edna" last="Schechtman">Edna Schechtman</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Industrial Engineering and Management, Ben Gurion University, Beer Sheva, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Industrial Engineering and Management, Ben Gurion University, Beer Sheva</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Miniowich, Ala" sort="Miniowich, Ala" uniqKey="Miniowich A" first="Ala" last="Miniowich">Ala Miniowich</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Strugatsky, Rosa" sort="Strugatsky, Rosa" uniqKey="Strugatsky R" first="Rosa" last="Strugatsky">Rosa Strugatsky</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurology, Hillel Yaffe Medical Center, Hadera, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Hillel Yaffe Medical Center, Hadera</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurosciences, University of Pisa, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurosciences, University of Pisa</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurosciences, University of Pisa, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurosciences, University of Pisa</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Rossi, Carlo" sort="Rossi, Carlo" uniqKey="Rossi C" first="Carlo" last="Rossi">Carlo Rossi</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurosciences, University of Pisa, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurosciences, University of Pisa</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Klein, Colin" sort="Klein, Colin" uniqKey="Klein C" first="Colin" last="Klein">Colin Klein</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Rabey, J Martin" sort="Rabey, J Martin" uniqKey="Rabey J" first="J. Martin" last="Rabey">J. Martin Rabey</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:AEBB6144CDA4BCBA8F00BF9EDBF063AD31C40036</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20968</idno>
<idno type="url">https://api.istex.fr/document/AEBB6144CDA4BCBA8F00BF9EDBF063AD31C40036/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001352</idno>
<idno type="wicri:Area/Istex/Curation">001352</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Association between amantadine and the onset of dementia in Parkinson's disease</title>
<author>
<name sortKey="Inzelberg, Rivka" sort="Inzelberg, Rivka" uniqKey="Inzelberg R" first="Rivka" last="Inzelberg">Rivka Inzelberg</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurology, Hillel Yaffe Medical Center, Hadera, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Hillel Yaffe Medical Center, Hadera</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurosciences, University of Pisa, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurosciences, University of Pisa</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Schechtman, Edna" sort="Schechtman, Edna" uniqKey="Schechtman E" first="Edna" last="Schechtman">Edna Schechtman</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Industrial Engineering and Management, Ben Gurion University, Beer Sheva, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Industrial Engineering and Management, Ben Gurion University, Beer Sheva</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Miniowich, Ala" sort="Miniowich, Ala" uniqKey="Miniowich A" first="Ala" last="Miniowich">Ala Miniowich</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Strugatsky, Rosa" sort="Strugatsky, Rosa" uniqKey="Strugatsky R" first="Rosa" last="Strugatsky">Rosa Strugatsky</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurology, Hillel Yaffe Medical Center, Hadera, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Hillel Yaffe Medical Center, Hadera</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurosciences, University of Pisa, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurosciences, University of Pisa</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurosciences, University of Pisa, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurosciences, University of Pisa</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Rossi, Carlo" sort="Rossi, Carlo" uniqKey="Rossi C" first="Carlo" last="Rossi">Carlo Rossi</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurosciences, University of Pisa, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurosciences, University of Pisa</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Klein, Colin" sort="Klein, Colin" uniqKey="Klein C" first="Colin" last="Klein">Colin Klein</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Rabey, J Martin" sort="Rabey, J Martin" uniqKey="Rabey J" first="J. Martin" last="Rabey">J. Martin Rabey</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-09">2006-09</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1375">1375</biblScope>
<biblScope unit="page" to="1379">1379</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">AEBB6144CDA4BCBA8F00BF9EDBF063AD31C40036</idno>
<idno type="DOI">10.1002/mds.20968</idno>
<idno type="ArticleID">MDS20968</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Parkinson's disease</term>
<term>amantadine</term>
<term>dementia</term>
<term>selegiline</term>
<term>therapy</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The objective of this study is to compare the occurrence of dementia among Parkinson's disease (PD) patients treated with amantadine (AM group) with those never exposed to it (NoAM group). PD dementia shares neuroanatomical and biochemical similarities with Alzheimer's disease (AD). Memantine, an N‐methyl‐D‐aspartate (NMDA) receptor antagonist has been shown to be beneficial in AD. Memantine is a dimethyl derivative of amantadine, which also possesses NMDA receptor blocking properties. We hypothesized that amantadine could have a beneficial effect on the occurrence of PD dementia. PD patients attending the Movement Disorders Clinics in Hillel Yaffe, Asaf Harofe Medical Centers (Israel) and Pisa (Italy) were included. Taking the onset of dementia as the endpoint, survival curves for AM and NoAM patients were estimated by the Kaplan–Meier method. The study population consisted of 593 patients (age, 69.5 ± 9.9 years; PD duration, 9.2 ± 6.0 years; 263 patients (44%) amantadine treated). The endpoint of dementia was reached by 116 patients (20%). PD duration until dementia was significantly longer for AM patients (9.1 ± 5.7 years) than for NoAM patients (5.9 ± 4.6 years, P = 0.006). The duration of amantadine exposure positively correlated with PD duration until dementia (P = 0.0001). Survival analysis, taking dementia onset as endpoint, showed slower mental decline in AM patients (Log rank P = 0.0049, Wilcoxon P = 0.0024). Mini‐Mental State Examination scores were significantly higher for AM patients than for the NoAM group (P = 0.01). Age of PD onset also significantly influenced the duration of PD until dementia. Amantadine use may delay the onset of dementia in PD patients and may attenuate its severity. © 2006 Movement Disorder Society</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001352 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001352 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Istex
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:AEBB6144CDA4BCBA8F00BF9EDBF063AD31C40036
   |texte=   Association between amantadine and the onset of dementia in Parkinson's disease
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024